In an observational comparative effectiveness study of targeted vs non-targeted therapy for metastatic renal cell carcinoma (mRCC), older patients saw modest survival advantages when treated with targeted therapies. The retrospective study showed that a broader range of patients than previously thought were potentially candidates for the less toxic targeted therapies. Learn more by clicking here.